Comparison of programmed death ligand 1 immunostaining for pancreatic ductal adenocarcinoma between paired cytological and surgical samples

OBJECTIVES: Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis with surgery or chemotherapy. Programmed death ligand 1 expression (PD-L1) immunotherapy has been successful for treating lung and other cancers with PD-L1 expression. However, in many unresectable PDAC cases, cytological sampl...

Descripción completa

Detalles Bibliográficos
Autores principales: Muggilli, Michael, Russell, Donna, Zhou, Zhongren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Scientific Scholar 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8645468/
https://www.ncbi.nlm.nih.gov/pubmed/34876919
http://dx.doi.org/10.25259/Cytojournal_78_2020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8645468/
https://www.ncbi.nlm.nih.gov/pubmed/34876919
http://dx.doi.org/10.25259/Cytojournal_78_2020

Ejemplares similares